Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Motrin Suspension

This article was originally published in The Tan Sheet

Executive Summary

Waxman/Hatch marketing exclusivity reportedly extended for up to an additional 180 days under FDAMA provision that extends exclusivity for studies in pediatric populations. McNeil applied for an extension based on its earlier switch trial. Exclusivity for the product was set to expire June 16. Alpharma and Perrigo have entered into a joint licensing agreement to market, sell and distribute the OTC children's ibuprofen suspension in the U.S. The launch is expected to coincide with FDA's final approval in late 1998, Alpharma says...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel